James R. Kasinger - Dec 3, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
General Counsel and Secretary
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Dec 3, 2022
Transactions value $
-$169,009
Form type
4
Date filed
12/6/2022, 04:47 PM
Previous filing
Oct 12, 2022
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +6.67K +14.26% 53.4K Dec 3, 2022 Direct F1, F2, F3
transaction CRSP Common Shares Tax liability -$169K -3.23K -6.05% $52.26 50.2K Dec 5, 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -6.67K -100% 0 Dec 3, 2022 Common Shares 6.67K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 Includes 329 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
F4 On December 3, 2019, the reporting person was granted 20,000 restricted stock units. On December 3, 2022, 6,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.